ImmunoGen appoints Tracey McCain to its Board of Directors

– USA, MA –  ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced the appointment of Tracey McCain, Esq. to its Board of Directors.

“We are thrilled to have Tracey join ImmunoGen’s Board of Directors at this critical juncture for the Company,” said Board Chairman, Steve McCluski. “As ImmunoGen awaits top-line data from the pivotal SORAYA trial for mirvetuximab soravtansine in ovarian cancer this quarter, continues to advance its pipeline, and prepares for potential commercialization next year, Tracey’s impressive legal background supporting a variety of corporate initiatives will be instrumental to the Board and management team in ensuring the Company continues to have best-in-class governance and compliance measures in place.”

About Tracey L. McCain

Tracey McCain has more than 20 years of legal, management, and transactional experience in the biopharmaceutical industry and currently serves as the EVP and Chief Legal and Compliance Officer at Blueprint Medicines Corporation. Before joining Blueprint, she served as SVP and Head of Legal for Sanofi Genzyme, was a member of the executive leadership team, and was a member of the leadership team for Sanofi’s global legal department. Before that, Ms. McCain served as Genzyme’s general counsel after it was acquired by Sanofi in 2011. In her capacity as Genzyme’s general counsel, Ms. McCain was responsible for all aspects of its legal department in the U.S. and throughout Europe, including general corporate, commercial and intellectual property matters, and support of business development initiatives. Before Genzyme’s acquisition, Ms. McCain was also responsible for managing the securities and employment law teams and support of non-patent litigation. Before Genzyme, Ms. McCain was an associate at the law firm Palmer & Dodge LLP.

Ms. McCain said, “I’m excited to join ImmunoGen’s Board during this pivotal time, as the Company approaches an important clinical readout, while simultaneously progressing the rest of its pipeline of novel ADCs. I look forward to offering my expertise and working with ImmunoGen’s leadership as the Company looks to transition into a fully integrated oncology company next year.”

She received her B.A. from the University of Pennsylvania and her J.D. from Columbia University School of Law.

About ImmunoGen

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.